China Medical System Holdings Limited (HKG: 0867)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 17.50B |
| Revenue (ttm) | 7.54B |
| Net Income (ttm) | 1.49B |
| Shares Out | 2.42B |
| EPS (ttm) | 0.61 |
| PE Ratio | 11.85 |
| Forward PE | 8.66 |
| Dividend | 0.42 (5.81%) |
| Ex-Dividend Date | Aug 29, 2024 |
| Volume | 2,142,000 |
| Average Volume | 4,613,077 |
| Open | 7.10 |
| Previous Close | 7.18 |
| Day's Range | 7.10 - 7.25 |
| 52-Week Range | 6.23 - 13.16 |
| Beta | 0.93 |
| RSI | 48.08 |
| Earnings Date | Mar 14, 2025 |
About China Medical System Holdings
China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China. Its products include VALTOCO, a diazepam nasal spray to treat seizure clusters; Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu to treat acute heart failure; Deanxit for mild-to-moderate depression, anxiety, and psychosomatic affections; METOJECT, a methotrexate injection for recalcitrant disabling psoriasis; and Ursofalk for the treatment of ch... [Read more]
Financial Performance
In 2023, China Medical System Holdings's revenue was 8.01 billion, a decrease of -12.43% compared to the previous year's 9.15 billion. Earnings were 2.40 billion, a decrease of -26.33%.
Financial numbers in CNY Financial StatementsNews
Alpha Cognition Inks $44 Million Licensing Pact For Its Alzheimer's Drug In China
On Wednesday, Alpha Cognition Inc. (NASDAQ: ACOG) and China Medical System Holdings Limited announced an exclusive licensing agreement for the development, manufacturing, and commercialization of Zun...